Ascendis Pharma A/S (ASND.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|42||2013||Chairman of the Board, Senior Vice President, General Counsel|
|56||2007||President, Chief Executive Officer, Director|
|2016||Chief Financial Officer, Senior Vice President|
|53||2007||Senior Vice President, Chief Administrative Officer|
|45||2007||Senior Vice President, Chief Scientific Officer|
- BRIEF-Ascendis Pharma A/S Q3 loss per share EUR 1.04
- BRIEF-Ascendis Pharma A/S prices public offering of 3.8 mln shares at $35.50 per ADS
- BRIEF-Ascendis Pharma A/S announces proposed public offering of ADSs
- BRIEF-Ascendis Pharma A/S reports dosing of subjects in phase 1 trial of transcon pth
- BRIEF-Ascendis Pharma Q2 loss per share EUR 0.94